Guggenheim Maintains Buy on Eli Lilly (LLY) After “Another Impressive Year”

Eli Lilly and Company (NYSE:LLY) is included among the 14 Best US Stocks to Buy for Long Term.

Guggenheim Maintains Buy on Eli Lilly (LLY) After “Another Impressive Year”

On December 3, Guggenheim raised its price target on Eli Lilly and Company (NYSE:LLY) to $1,163 from $1,036 and kept a Buy rating on the stock. The firm updated its models for LLY based on prescription trends and GLP-1 pricing news. While highlighting that the company “delivered another impressive year of stock performance in 2025,” the firm “simply cannot argue with the company’s superior overall execution capitalizing fully on the Pharma mega cycle of our lifetime,” the analyst tells investors.

Eli Lilly and Company (NYSE:LLY) has performed exceptionally well over the past few years, gaining over 580% in the past five years. One of the reasons for this growth is the company’s strengths in the weight loss drug market. Its potential weight loss pill, orforglipron, could be the company’s new growth driver. In its recent earnings news, LLY declared that orforglipron showed encouraging results in late-stage trials. The company also plans to seek regulatory approval for its use in obesity before the year ends.

Overall, Eli Lilly and Company (NYSE:LLY) delivered revenue of $17.6 billion in the third quarter of 2025, which showed a staggering growth of 53.8% from the same period last year. The revenue surpassed analysts’ estimates by $1.53 billion. The revenue growth drivers were mainly Mounjaro and Zepbound. These drugs also performed remarkably well, with Mounjaro’s worldwide revenue surging by 10% and Zepbound’s by 184%.

Eli Lilly and Company (NYSE:LLY) is an American multinational pharmaceutical company that discovers and markets a wide range of pharmaceuticals.

While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LLY and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 15 Blue Chip Dividend Stocks to Build a Passive Income Portfolio and 15 Dividend Stocks That Outperform the S&P 500.

Disclosure: None.